Abstract
Purpose
Pro- and antiinflammatory cytokines are important modulators of the immune response
and play a major role in conditions of intestinal inflammation, such as irritable
bowel syndrome (IBS). Cytokine production is regulated genetically, and imbalances
in cytokine secretion may affect disease susceptibility and clinical outcomes of various
conditions. There is a rapidly growing body of evidence to support an etiologic role
for gastrointestinal infection and the associated immune activation in the development
of postinfectious IBS. Other factors such as psychological stress, anxiety, and depression
may likely be involved in the altered profiles of pro- and antiinflammatory cytokines
that lead to chronic IBS.
Methods
We searched the literature using PubMed, MEDLINE, and Google Scholar with related
key terms and prepared this review article on that basis.
Findings
Interleukin (IL)-10 is a regulatory cytokine that inhibits both antigen presentation
and the release of proinflammatory cytokines. Therefore, it is proposed as a potent
antiinflammatory biological therapy for IBS.
Implications
Recently, a strong interest in the therapeutic potential of IL-10 for IBS has developed.
The diverse roles of IL-10 in IBS are reviewed here. We conducted an in-depth review
on IL-10 and IBS to address this question. Future studies of IL-10 may provide new
insights into IBS therapy.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
ReferenceS
- The immune system in irritable bowel syndrome.J Neurogastroenterol Motil. 2011; 17: 349-359
- Unraveling the ties between irritable bowel syndrome and intestinal microbiota.World J Gastroenterol. 2014; 20: 2470-2481
- The gut microbiota and irritable bowel syndrome: friend or foe?.Int J Inflam. 2012; 2012: 151085
- Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis.Dig Dis Sci. 2015; 60: 2953-2962
- The treatment of irritable bowel syndrome.Therap Adv Gastroenterol. 2009; 2: 221-238
- Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?.Am J Gastroenterol. 2013; 108: 1066-1074
- Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.Nat Rev Gastroenterol Hepatol. 2010; 7: 163-173
- Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.Nat Rev Gastroenterol Hepatol. 2014; 12: 36-49
- Two types of mouse T helper cell. IV.Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989; 170: 2081-2095
- Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1.Science. 1990; 250: 830-832
- IL-10 and its related cytokines for treatment of inflammatory bowel disease.World J Gastroenterol. 2004; 10: 620-625
- Interleukin-10 therapy—review of a new approach.Pharmacol Rev. 2003; 55: 241-269
- Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease.Curr Allergy Asthma Rep. 2012; 12: 373-379
- The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes.J Interferon Cytokine Res. 1999; 19: 563-573
- Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster.Genome Res. 1999; 9: 242-250
- Macrophage deactivation by interleukin 10.J Exp Med. 1991; 174: 1549-1555
- Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.Gastroenterology. 1995; 108: 1434-1444
- Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1beta and TNFalpha: effects of IL-10 and corticosteroids.Br J Pharmacol. 1999; 127: 1145-1150
- Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action.Biochem Biophys Res Commun. 2000; 273: 811-815
- Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico.Am J Gastroenterol. 2012; 107: 747-753
- Changes of cytokine levels in a mouse model of post-infectious irritable bowel syndrome.BMC Gastroenterol. 2015; 15: 43
- IL-10 and TNF-alpha polymorphisms in subjects with irritable bowel syndrome in Mexico.Rev Esp Enferm Dig. 2013; 105: 392-399
- Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: a meta-analysis.World J Gastroenterol. 2013; 19: 9472-9480
- Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome.Am J Gastroenterol. 2005; 100: 2510-2516
- Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?.Gut. 2003; 52: 91-93
- S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome.Dig Dis Sci. 2013; 58: 2314-2323
- [A study of interleukin-10 gene polymorphism in irritable bowel syndrome].Zhonghua Nei Ke Za Zhi. 2006; 45: 289-292
- Interleukin-8 and -10 gene polymorphisms in irritable bowel syndrome.Mol Biol Rep. 2012; 39: 8837-8843
- Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis.Parasitol Res. 2012; 111: 487-491
- Cytokine gene polymorphisms in irritable bowel syndrome in Indian population—a pilot case control study.Trop Gastroenterol. 2010; 31: 30-33
- G protein beta3 subunit, interleukin-10, and tumor necrosis factor-alpha gene polymorphisms in Koreans with irritable bowel syndrome.Neurogastroenterol Motil. 2010; 22: 758-763
- T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome.Inflammation. 2010; 33: 281-286
- Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome.BMC Gastroenterol. 2012; 12: 91
- IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes.Clin Exp Immunol. 2000; 119: 426-432
- Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome.Exp Ther Med. 2013; 6: 93-96
- Mucosal cytokine imbalance in irritable bowel syndrome.Scand J Gastroenterol. 2008; 43: 1467-1476
- Immune dysfunction in patients with functional gastrointestinal disorders.Neurogastroenterol Motil. 2009; 21: 389-398
- Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol. 2012; 303: G775-G785
- Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome.J Gastroenterol. 2014; 49: 1467-1476
- Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia.Am J Gastroenterol. 2011; 106: 1089-1098
- Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes.Gut. 2013; 62: 1456-1465
- Serum and colonic mucosal immune markers in irritable bowel syndrome.Am J Gastroenterol. 2012; 107: 262-272
- Imbalance of tumor necrosis factor-alpha, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea.Mol Med Rep. 2015; 12: 5239-5245
- Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome.PLoS One. 2014; 9: e93144
- Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting.Scand J Gastroenterol. 2012; 47: 619-624
- Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome.Neurogastroenterol Motil. 2009; 21: 149-159
- Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?.Gastroenterol. 2006; 130: 304-311
- Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria.BMC Immunol. 2009; 10: 54
- Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults.World J Gastroenterol. 2008; 14: 2029-2036
- Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells.Gut. 2012; 61: 354-366
- Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease.Curr Opin Gastroenterol. 2013; 29: 184-189
- Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.Gastroenterol. 2005; 128: 541-551
- Role of probiotics in the treatment of irritable bowel syndrome: potential mechanisms and current clinical evidence.Int J Probiotics Prebiotics. 2006; 1: 11
- Modulation of human dendritic cell phenotype and function by probiotic bacteria.Gut. 2004; 53: 1602-1609
- Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.Eur J Gastroenterol Hepatol. 2014; 26: 630-639
- [Efficacy of pectin in the treatment of diarrhea predominant irritable bowel syndrome.Zhonghua Wei Chang Wai Ke Za Zhi. 2015; 18: 267-271
- Interleukin-10 producing Lactococcus lactis for the treatment of Crohn׳s disease.Gastroenterol. 2005; 128 (A104-A104)
- Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.Hum Vaccin Immunother. 2014; 10: 1611-1621
- Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.Nat Biotechnol. 2003; 21: 785-789
- Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.Science. 2000; 289: 1352-1355
- Treatment of Crohn׳s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.Gut. 2002; 50: 191-195
- Control of intestinal inflammation by regulatory T cells.Immunol Rev. 2001; 182: 190-200
- Regulatory T cells and inflammatory bowel disease.Immunol Today. 1999; 20: 442-445
- Towards a systems view of IBS.Nat Rev Gastroenterol Hepatol. 2015; 12: 592-605
- Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients.Trop Gastroenterol. 2012; 33: 251-256
- Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.Gut. 2000; 47: 804-811
- Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection.Gut. 2004; 53: 1082-1089
- Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis.Neurogastroenterol Motil. 2014; 26: 1036-1048
- Prevalence of irritable bowel syndrome: a community based study from northern India.J Neurogastroenterol Motil. 2011; 17: 82-87
- Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase.Mediators Inflamm. 2006; 2006: 26875
- Colitis-induced bone loss is gender dependent and associated with increased inflammation.Inflamm Bowel Dis. 2013; 19: 1586-1597
- Immune sexual dimorphism: effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation.J Steroid Biochem Mol Biol. 2009; 113: 57-64
- Of depression and immunity: does sex matter?.Int J Neuropsychopharmacol. 2010; 13: 675-689
- Endogenous suppression of mast cell development and survival by IL-4 and IL-10.J Leukoc Biol. 2009; 85: 826-836
- The effect of irritable bowel syndrome on health-related quality of life and health care expenditures.Gastroenterol Clin North Am. 2011; 40: 11-19
- [Quality of life in irritable bowel syndrome].Nihon Rinsho. 2006; 64: 1540-1543
- Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome.Am J Gastroenterol. 2016; 111: 1165-1176
Article info
Publication history
Published online: February 24, 2017
Accepted:
January 18,
2017
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
